FDA Approves Differin Epiduo Acne Gel NDA220736 by Galderma
The FDA has approved Differin Epiduo Acne Gel (NDA220736), containing adapalene and benzoyl peroxide, submitted by Galderma Laboratories.
Company
Pharmaceutical intelligence for Galderma Laboratories with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.